Eli Lilly Stock Falls 8% on Lower-than-Expected Zepbound Sales Forecast
Eli Lilly Stock Falls 8% on Lower-than-Expected Zepbound Sales Forecast Eli Lilly’s shares dropped 8% on Tuesday after the pharmaceutical giant forecast fourth-quarter sales for its weight-loss drug Zepbound below Wall Street
